BC Week In Review | Oct 26, 2018
Clinical News

Castle Creek discontinues Phase II of epidermolysis bullosa compound

Castle Creek Pharmaceuticals LLC (Parsippany, N.J.) discontinued the Phase II DELIVERS trial evaluating topical 1% diacerein (AC-203, CCP-020) to treat epidermolysis bullosa simplex (EBS). According to ClinicalTrials.gov, an IDMC said the trial will not meet...
BC Week In Review | Sep 15, 2017
Company News

Allergan partners with tribe to fight IPR

In an effort to create a shield against patent challenges under the U.S. Patent and Trademark Office’s inter partes review process, Allergan plc (NYSE:AGN) announced Sept. 8 that it had transferred ownership of six patents...
BC Extra | Sep 9, 2017
Company News

Allergan partners with tribe to fight IPR

In an effort to create a shield against patent challenges under the U.S. Patent and Trademark Office’s inter partes review process, Allergan plc (NYSE:AGN) announced Friday that it had transferred ownership of six patents covering...
BC Week In Review | Jul 14, 2017
Clinical News

Castle Creek begins Phase II/III of topical diacerein to treat epidermolysis bullosa simplex

Castle Creek Pharmaceuticals LLC (Parsippany, N.J.) began the Phase II/III DELIVERS trial to evaluate topical 1% diacerein (AC-203, CCP-020) in about 80 patients ages ≥4 with epidermolysis bullosa simplex. The double-blind, international trial will test...
BC Week In Review | Dec 30, 2016
Financial News

TWi Pharmaceuticals financial update

The TWi Biotechnology Inc. subsidiary of TWi Pharmaceuticals began the formal process to list on the Taipei Exchange in Taiwan by applying as an emerging stock on the exchange. The company began trading as an...
BC Extra | Oct 3, 2016
Financial News

Rare disease play Castle Creek raises $48M

Specialty dermatology and ear, nose and throat company Castle Creek Pharmaceuticals LLC (Bedminster, N.J.) raised $48 million in a series A round from Fidelity. This quarter, the company expects to begin a pivotal Phase II/III...
BC Extra | Aug 31, 2016
Company News

Management tracks

The European Federation of Pharmaceutical Industries and Associations (EFPIA) said Richard Bergstroem is departing as director general. EFPIA has begun a search for a replacement. Jean Pierre Wery became CEO of the Crown Bioscience subsidiary...
BC Innovations | Aug 11, 2016
Distillery Therapeutics

Therapeutics: Integrin β3 (GPIIIa; CD61); integrin αvβ3 (CD51/CD61)

Autoimmune disease INDICATION: Multiple sclerosis Mouse studies suggest inhibiting integrin β3 or integrin αvβ3 could help treat MS. In CNS T helper type 17 (Th17) cells or in lymph nodes of the experimental autoimmune encephalomyelitis...
BC Innovations | May 12, 2016
Targets & Mechanisms

Another shot at the flu

While most efforts to suppress flu focus on boosting the immune system through vaccination, a group at Yale University has found evidence showing it is the inflammatory response to infection, not the infection itself, that...
BC Week In Review | Jan 11, 2016
Clinical News

AC-201 CR: Interim Phase IIa data

Interim data from 36 gout patients in the first cohort of the double-blind, Taiwanese Phase IIa AC-201-GOU-002 trial showed that twice-daily oral AC-201 CR met the criteria of >=2 more responders, defined as achieving a...
Items per page:
1 - 10 of 36